Expect no end from the wild ride in Biotech (IBB) stocks. On a macro level, the buyout of Medivation (MDVN) from Sanofi (SNY) will lift biotech stocks. Even Medivation rejecting the offer on grounds that the bid is too low will help the sector.Investors will worry less about generic drug pricing if the deal for Teva Pharmaceuticals (TEVA) to buy Allergan’s (AGN) generic drugs unit gets approval from regulators. Both need this deal to move forward. Allergan benefits by using the proceeds of the sale ($40.5 billion) to buy back shares and cut its debt. Teva may consolidate its generic drugs portfolio, cutting costs and operating more effectively. Regulatory approval depends on Teva shedding assets.On June 28, Mayne Pharma acquired 42 generic products from Teva. The deal is worth $652 million.Regulators in Europe and the U.S. fret over the dominance Teva will have as the world’s largest generic maker. Teva received approval from European regulators in March and await a decision from the Federal Trade Commission.Biotech stocks indirectly benefiting from this transaction: Valeant Pharmaceuticals (VRX): Scrutiny from government on generic drug sales practices will lessenEndo International (ENDP). Company seeks to improve profit margin on generic drug business